Recent advancements in cancer genetics and the rise of targeted therapies, solid tumor profiling has proven essential in determining the most effective treatment options for patients. As molecular pathology labs test more genomic targets, Dr. Darryl Irwin, Vice President of Scientific Affairs at Agena Bioscience®, shares how labs can use these opportunities to improve cancer treatment while maintaining high-quality customer results.

Dr. Irwin has identified the three main areas where molecular pathology labs can enhance cancer care for their customers and patients

In this article, you’ll discover:

  • How to make a significant contribution to improving the overall quality of patient care

  • check-icon

    What failure rates mean for patient treatment options

  • How to expand access of broad molecular tumor profiling

ONCTP-Inset-C-06
ONCTP-Inset-C-06

Download PDF

Access The Article

Complete the form to download this informative article from Dr. Darryl Irwin: "Three Opportunities for Labs to Lead Improvements in Cancer Treatment".

As more treatment options become available, the set of clinically actionable genomic targets a molecular pathology lab is asked to test has expanded significantly.”

Darryl Irwin, PhD
Darryl Irwin, PhD

VP of Scientific Affairs, Agena Bioscience

About Agena Bioscience

At Agena Bioscience, we are dedicated to advancing the impact of genomics in healthcare and precision medicine.

Connect

© 2023 Agena Bioscience